Search

Your search keyword '"Ahmad, Tanya"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Ahmad, Tanya" Remove constraint Author: "Ahmad, Tanya"
38 results on '"Ahmad, Tanya"'

Search Results

1. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx

2. The evolution of non-small cell lung cancer metastases in TRACERx

3. The evolution of lung cancer and impact of subclonal selection in TRACERx

4. 102 Hepatitis B and HIV screening prior to first systemic anticancer therapy (SACT) in an inner-city London thoracic cancer population.

5. 95 Lorlatinib in advanced ALK-rearranged NSCLC – real-world experience in a UK population

6. 84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer

8. Body composition and lung cancer-associated cachexia in TRACERx

9. The evolution of lung cancer and impact of subclonal selection in TRACERx

10. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

12. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

13. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

14. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

16. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

17. Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

18. LUNG CANCER EVOLUTION: Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

21. Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue

23. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies

24. Fc-Optimized Anti-CD25 depletes tumor-infiltrating regulatory T Cells and synergizes with PD-1 Blockade to eradicate established tumors

25. Cell-free circulating tumour DNA (ctDNA) in the management of patients (pts) with non-biopsiable (Bx) advanced non-small cell lung cancer (NSCLC).

26. Erratum: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

27. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

28. Tracking the Evolution of Non–Small-Cell Lung Cancer

29. P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)

31. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

32. Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

36. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

Catalog

Books, media, physical & digital resources